PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer.
Fengyun PeiWan HeYinghua DuanQijun YaoYandong ZhaoXinjuan FanShuai LiuHaiyang ChenFang HeTingzhi LiuJiaoting ChenYijia ZhengHeping LiXiaofang GuoLishuo ShiLi LingYaoxu ChenJiapeng HeMiao LiuMengli HuangYuezong BaiJianping WangMeijin HuangJun HuangPublished in: Cancer medicine (2024)
Neoadjuvant sintilimab combined with bevacizumab and mFOLFOX6 was associated with few side effects, did not delay surgery, and led to pCR and non-pCR in 54.5% and 81.8% of the cases, respectively. Downregulation of CD3/CD4 expression in the tumor and stroma is related to pCR. However, the molecular mechanisms underlying PD-1 blockade-enhanced targeted chemotherapy require further investigation.
Keyphrases
- locally advanced
- rectal cancer
- phase ii study
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- cancer therapy
- minimally invasive
- poor prognosis
- real time pcr
- metastatic colorectal cancer
- cell proliferation
- coronary artery bypass
- binding protein
- clinical trial
- surgical site infection
- long non coding rna